FLUICELL AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0962 SEK | -5.22% |
|
-4.75% | -84.78% |
| May. 10 | Fluicell AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 08 | Fluicell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2022 | 3.25M 314K | Sales 2023 | 3.34M 322K | Capitalization | 17.2M 1.66M |
|---|---|---|---|---|---|
| Net income 2022 | -21M -2.03M | Net income 2023 | -26M -2.51M | EV / Sales 2022 | 4.2 x |
| Net cash position 2022 | 24.46M 2.36M | Net cash position 2023 | 2.76M 267K | EV / Sales 2023 | 4.33 x |
| P/E ratio 2022 |
-1.89
x | P/E ratio 2023 |
-0.62
x | Employees | 16 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 69.78% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -5.22% | ||
| 1 week | -4.75% | ||
| Current month | -4.75% | ||
| 1 month | +4.79% | ||
| 3 months | -10.09% | ||
| 6 months | -45.03% | ||
| Current year | -84.78% |
1 week
0.09
0.11
1 month
0.080.12
Current year
0.081.00
1 year
0.081.86
3 years
0.0834.70
5 years
0.0843.80
10 years
0.0843.80
| Managers | Title | Age | Since |
|---|---|---|---|
Carolina Trkulja
CEO | Chief Executive Officer | 40 | - |
| Founder | 44 | 12-01-01 | |
| Director of Finance/CFO | 54 | 23-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jan Orwar
BRD | Director/Board Member | 60 | 14-12-31 |
Daniel T. Chiu
BRD | Director/Board Member | 52 | 16-12-31 |
Stefan Tilk
CHM | Chairman | 59 | 15-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 0.0962 | -5.22% | 1 032 976 |
| 24-06-05 | 0.1015 | +2.53% | 4,637,872 |
| 24-06-04 | 0.099 | +2.48% | 7,143,218 |
| 24-06-03 | 0.0966 | -4.36% | 4,731,334 |
| 24-05-31 | 0.101 | -3.81% | 5,242,726 |
Delayed Quote Nasdaq Stockholm, June 07, 2024 at 04:09 am EDT
More quotes
Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Companyâs products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.
Calendar
2024-08-15
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -84.78% | 3.2M | |
| +55.55% | 59.28B | |
| +42.83% | 40.94B | |
| -4.71% | 40.17B | |
| -5.56% | 28.69B | |
| +13.76% | 26.63B | |
| -22.00% | 18.89B | |
| +31.50% | 12.46B | |
| +2.16% | 12.42B | |
| +25.70% | 12.26B |
- Stock Market
- Equities
- FLUI Stock
